Ocugen-Bharat Biotech Covid vaccine meets main goals in US trial: Report

Ocugen Inc said on Monday the COVID-19 vaccine developed by its Indian partner Bharat Biotech International Ltd met the main goals of a trial in the United States

Ocugen-Bharat Biotech COVID vaccine meets main goals in U.S. trial
Ocugen-Bharat Biotech COVID vaccine meets main goals in U.S. trial
Reuters
1 min read Last Updated : Jan 09 2023 | 5:38 PM IST

(Reuters) -Ocugen Inc said on Monday the COVID-19 vaccine developed by its Indian partner Bharat Biotech International Ltd met the main goals of a trial in the United States, sending shares of the U.S. biotech firm 20% higher in premarket trade.

The vaccine, sold under brand name Covaxin, showed an immune response in individuals who had not received a COVID vaccine previously as well as those vaccinated with mRNA vaccines by Pfizer Inc and Moderna Inc, meeting its main goals, Ocugen said.

The vaccine was also found to be well-tolerated in both sets of participants, the company said.

(Reporting by Leroy Leo in Bengaluru; Editing by Savio D'Souza and Shinjini Ganguli)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Bharat BiotechCoronavirus VaccineUS

First Published: Jan 09 2023 | 5:38 PM IST

Next Story